Skip to main content
Ascentage Pharma adds lisaftoclax to China reimbursement list
Image for illustrative purposes only. Not a real photo.

Ascentage Pharma adds lisaftoclax to China reimbursement list

By

Key points

  • Ascentage Pharma (NASDAQ:AAPG) secured first-time Chinese national reimbursement coverage for lisaftoclax, while olverembatinib secured renewed coverage.
  • Ascentage Pharma shares last closed at $14.62 on November 13, down 2.66% during the session.
  • The updated reimbursement list takes effect January 1, 2027, covering all approved indications for both drugs and potentially expanding patient access in China.

Ascentage Pharma (NASDAQ:AAPG) secured first-time Chinese national reimbursement coverage for lisaftoclax and renewed coverage for olverembatinib, with the updated agreements taking effect January 1, 2027.

Lisaftoclax was added for adults with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who previously received at least one systemic treatment including a Bruton’s tyrosine kinase (BTK) inhibitor, while olverembatinib retained coverage for eligible chronic myeloid leukemia (CML) patients.

Olverembatinib's renewed coverage includes adults with chronic-phase CML resistant or intolerant to first- and second-generation tyrosine kinase inhibitors, alongside adults with chronic- or accelerated-phase CML carrying the T315I mutation, bringing all approved indications for both drugs under the reimbursement list.

Lisaftoclax is an oral selective Bcl-2 inhibitor approved in China in July 2025, while olverembatinib is an oral third-generation BCR-ABL inhibitor approved in November 2021 and jointly commercialized in China with Innovent Biologics.

The reimbursement expansion supports Ascentage Pharma's commercialisation efforts in China, although neither drug has received U.S. Food and Drug Administration approval, according to the company.


Frequently asked questions